Notice of Proposed Sale · 144
Harrow, Inc.
HROWNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- HARROW, INC.
- Issuer CIK
- 0001360214
- SEC file number
- 001-35814
- Phone
- 615-733-4730
- Person for whose account securities are to be sold
- AMIR SHOJAEI
- Relationships to issuer
- CHIEF SCIENTIFIC OFFICER
- Street
- 1A BURTON HILLS BLVD., SUITE 200,
- City
- NASHVILLE,
- State / country code
- TN
- Postal code
- 37215
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON STOCK | 11,250 | 450,000.00 | 37,487,850 | 08/14/2026 | NASDAQ STOCK MARKET | MORGAN STANLEY SMITH BARNEY |
Broker / market maker — proposed row 1, entry 1
- Name
- MORGAN STANLEY SMITH BARNEY
- Street
- 2000 WESTCHESTER
- Street (continued)
- AVE PURCHASE,
- City
- NY
- State / country code
- NY
- Postal code
- 10577-2530
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON STOCK | 08/14/2026 | OPTION EXERCISE | HARROW, INC. | 11,250 | N | 08/14/2026 | Cash via broker-assisted same day sale proceeds |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
This Form 144 is being filed after the sale date due to an inadvertent administrative oversight. The Form 144 reports a broker-assisted same-day sale transaction effected on August 14, 2026 in connection with the exercise of employee stock options.
Notice signature
- Notice date
- 08/21/2026
- Signed
- Andrew R. Boll, attorney in fact for Amir Shojaei
Company context
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn (www.linkedin.com/company/harrow-health-inc/).
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureOct 5, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 4, 2026
- 10-Q filingAug 10, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 10, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 6, 2026